Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Mirum Pharmaceuticals, Inc. - common stock (NQ:MIRM)

103.50 -6.58 (-5.98%)

Streaming Delayed Price Updated: 3:27 PM EDT, May 7, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	1,596,681
Open	110.08
Bid (Size)	103.24 (100)
Ask (Size)	103.90 (400)
Prev. Close	110.08
Today's Range	98.59 - 112.00
52wk Range	40.00 - 110.49
Shares Outstanding	38,297,975
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Penn Capital Unloads 1.13 Million RealReal Shares Following Massive Stock Run-Up ↗

Today 10:05 EDT

This online marketplace connects U.S. consumers with consigned luxury goods, spanning apparel, jewelry, art, and home products.

Via The Motley Fool

Mirum (MIRM) Q1 2026 Earnings Call Transcript ↗

May 06, 2026

Mirum (MIRM) Q1 2026 Earnings Call Transcript

Via The Motley Fool

Performance

YTD	+32.6%	+32.6%
1 Month	+7.5%	+7.5%
3 Month	-0.4%	-0.4%
6 Month	+47.7%	+47.7%
1 Year	+152.4%	+152.4%

More News

Mirum Pharmaceuticals (NASDAQ:MIRM) Stock Dips After Q1 Revenue Beat and Guidance Raise, Despite Massive IPR&D Charge ↗

May 06, 2026

Via Chartmill

Mirum Pharmaceuticals (NASDAQ:MIRM) Reports Q4 2025 Revenue Beat and 2026 Outlook ↗

February 25, 2026

Via Chartmill

Mirum Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update

May 06, 2026

From Mirum Pharmaceuticals, Inc.

Via Business Wire

Mirum Pharmaceuticals Announces Primary Endpoint Met in VISTAS Study of Volixibat in Patients with Primary Sclerosing Cholangitis

May 04, 2026

From Mirum Pharmaceuticals, Inc.

Via Business Wire

Mirum Pharmaceuticals to Host Investor Call to Share Topline Results from the VISTAS Study of Volixibat in Patients with Primary Sclerosing Cholangitis on May 4, 2026

May 03, 2026

From Mirum Pharmaceuticals, Inc.

Via Business Wire

Mirum Pharmaceuticals to Announce First Quarter 2026 Financial Results and Host Conference Call on May 6, 2026

April 29, 2026

From Mirum Pharmaceuticals, Inc.

Via Business Wire

Mirum Pharmaceuticals Announces Primary Endpoint Met in Phase 2b Portion of the AZURE-1 Study of Brelovitug in Chronic Hepatitis Delta Virus

April 27, 2026

From Mirum Pharmaceuticals, Inc.

Via Business Wire

2 Under-the-Radar Biotech Stocks Worth Buying for the Long Term ↗

April 19, 2026

Via The Motley Fool

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

April 13, 2026

From Mirum Pharmaceuticals, Inc.

Via Business Wire

Prediction: Buying This Biotech Stock Today Could Set You Up for Life ↗

April 13, 2026

Via The Motley Fool

Mirum (MIRM) Q2 2025 Earnings Call Transcript ↗

April 01, 2026

Via The Motley Fool

Mirum Pharma (MIRM) Earnings Call Transcript ↗

April 01, 2026

Via The Motley Fool

Mirum (MIRM) Q1 2025 Earnings Call Transcript ↗

April 01, 2026

Via The Motley Fool

Biotech Stock Up 372% Gets Sold as New Pick Rises 40% in 2026 ↗

March 20, 2026

Via The Motley Fool

This Biotech Stock Has Surged 250% in a Year as One Investor Discloses $10 Million New Position ↗

March 20, 2026

Via The Motley Fool

Mirum Pharmaceuticals Completes Enrollment in Phase 3 EXPAND Study of LIVMARLI® (maralixibat) in Additional Rare Cholestatic Liver Diseases

March 16, 2026

From Mirum Pharmaceuticals, Inc.

Via Business Wire

Hedge Fund Boone Capital Initiated a Stake in HealthEquity. Is the Stock a Buy? ↗

March 15, 2026

Via The Motley Fool

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

March 12, 2026

From Mirum Pharmaceuticals, Inc.

Via Business Wire

Small-Cap Shudder: Russell 2000’s 1.9% Slide Signals Cracks in Economic Resilience

March 05, 2026

Via MarketMinute

Mirum Pharmaceuticals Provides AZURE Clinical Program Update for brelovitug in Chronic Hepatitis Delta Virus

March 05, 2026

From Mirum Pharmaceuticals, Inc.

Via Business Wire

Mirum (MIRM) Q4 2025 Earnings Call Transcript ↗

February 25, 2026

Via The Motley Fool

Mirum Pharmaceuticals Reports Fourth Quarter and Year-End 2025 Results and Provides Business Update

February 25, 2026

From Mirum Pharmaceuticals, Inc.

Via Business Wire

ACM Research’s AI Surge Collides With Export Controls and Chip Spending Cycles ↗

February 25, 2026

Via The Motley Fool

Frequently Asked Questions

Is Mirum Pharmaceuticals, Inc. - common stock publicly traded?

Yes, Mirum Pharmaceuticals, Inc. - common stock is publicly traded.

What exchange does Mirum Pharmaceuticals, Inc. - common stock trade on?

Mirum Pharmaceuticals, Inc. - common stock trades on the Nasdaq Stock Market

What is the ticker symbol for Mirum Pharmaceuticals, Inc. - common stock?

The ticker symbol for Mirum Pharmaceuticals, Inc. - common stock is MIRM on the Nasdaq Stock Market

What is the current price of Mirum Pharmaceuticals, Inc. - common stock?

The current price of Mirum Pharmaceuticals, Inc. - common stock is 103.50

When was Mirum Pharmaceuticals, Inc. - common stock last traded?

The last trade of Mirum Pharmaceuticals, Inc. - common stock was at 05/07/26 03:27 PM ET

What is the market capitalization of Mirum Pharmaceuticals, Inc. - common stock?

The market capitalization of Mirum Pharmaceuticals, Inc. - common stock is 3.96B

How many shares of Mirum Pharmaceuticals, Inc. - common stock are outstanding?

Mirum Pharmaceuticals, Inc. - common stock has 4B shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.